Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin O Bergo

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Small Gtpases|July 15, 2016
What makes oncogenes mutually exclusive?Jaroslaw Cisowski, Martin O Bergo
Nature Medicine|July 2, 2002
Extra Rabs unsnarl a lipid traffic jamMartin O Bergo, Stephen G Young
Nature Metabolism|April 15, 2026
Overcoming dietary dogmasJon O Lundberg, Martin O Bergo
ACS Central Science|September 2, 2021
Toward a New Therapy for Rapidly Aging ChildrenMohamed X Ibrahim, Martin O Bergo
Circulation|November 26, 2019
Response by Akyürek et al to Letter Regarding Article, "Targeting Filamin A Reduces Macrophage Activity and Atherosclerosis"Levent M Akyürek, Martin O Bergo, Sashidar Bandaru
Expert Opinion on Therapeutic Targets|May 16, 2022
Progeria: a perspective on potential drug targets and treatment strategiesIgnacio Benedicto, Xue Chen, Martin O Bergo, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2011
RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segmentsJeffrey R Christiansen, Saravanan Kolandaivelu, Martin O Bergo, et al.
Basic & Clinical Pharmacology & Toxicology|July 5, 2022
Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modificationXue Chen, Haidong Yao, Vicente Andrés, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2004
Lamin B1 is required for mouse development and nuclear integrityLaurent Vergnes, Miklós Péterfy, Martin O Bergo, et al.
Aging Cell|March 21, 2020
The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypesAudrey Griveau, Clotilde Wiel, Dorian V Ziegler, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Small Gtpases|July 15, 2016
What makes oncogenes mutually exclusive?Jaroslaw Cisowski, Martin O Bergo
Nature Medicine|July 2, 2002
Extra Rabs unsnarl a lipid traffic jamMartin O Bergo, Stephen G Young
Nature Metabolism|April 15, 2026
Overcoming dietary dogmasJon O Lundberg, Martin O Bergo
ACS Central Science|September 2, 2021
Toward a New Therapy for Rapidly Aging ChildrenMohamed X Ibrahim, Martin O Bergo
Circulation|November 26, 2019
Response by Akyürek et al to Letter Regarding Article, "Targeting Filamin A Reduces Macrophage Activity and Atherosclerosis"Levent M Akyürek, Martin O Bergo, Sashidar Bandaru
Expert Opinion on Therapeutic Targets|May 16, 2022
Progeria: a perspective on potential drug targets and treatment strategiesIgnacio Benedicto, Xue Chen, Martin O Bergo, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2011
RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segmentsJeffrey R Christiansen, Saravanan Kolandaivelu, Martin O Bergo, et al.
Basic & Clinical Pharmacology & Toxicology|July 5, 2022
Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modificationXue Chen, Haidong Yao, Vicente Andrés, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2004
Lamin B1 is required for mouse development and nuclear integrityLaurent Vergnes, Miklós Péterfy, Martin O Bergo, et al.
Aging Cell|March 21, 2020
The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypesAudrey Griveau, Clotilde Wiel, Dorian V Ziegler, et al.
Pageof 9